

What is claimed:

- Sub A1
1. A method of treating diabetes in a subject, comprising
    - (a) administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population; and
    - (b) administering to the subject pancreatic islet cells from a donor.
  2. The method of claim 1, wherein the diabetes is Type I diabetes.
  3. The method of claim 1, wherein the diabetes is Type II diabetes.
  4. The method of claim 1, wherein the immunotoxin transiently reduces the subject's T cells in the blood and lymph nodes by at least one log unit.
  5. The method of claim 1, wherein the immunotoxin is a divalent anti-T cell immunotoxin directed at the CD3 epitope.
  6. The method of claim 5, wherein the divalent anti-T cell immunotoxin comprises a toxin moiety and a targeting moiety directed to the T cell CD3ε epitope.
  7. The method of claim 6, wherein the toxin moiety is a diphtheria toxin.
  8. The method of claim 5, wherein the divalent anti-T cell immunotoxin is UCHT1-CRM9.
  9. The method of claim 1 further comprising administering an immunosuppressive agent to the subject.
  10. The method of claim 9, wherein the immunosuppressive agents are administered beginning 0 to 24 hours prior to administration of the pancreatic islet cells to the recipient and continuing up to several weeks thereafter.
- Sub A2

- Side A B

[illegible]